Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 6 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 2 |
| Introduction | 12 | 17 |
| Symptoms | 12 | 1 |
| Etiology | 13 | 1 |
| Pathophysiology | 13 | 1 |
| Disease Initiation | 13 | 1 |
| Disease Propagation | 14 | 1 |
| Co-Morbidities and Complications | 15 | 1 |
| Diagnosis | 16 | 1 |
| Physical Examination | 16 | 1 |
| Blood Tests | 16 | 1 |
| Rheumatoid Factor Test | 16 | 1 |
| Anti-Citrullinated Protein Antibody | 16 | 1 |
| C-Reactive Protein | 16 | 1 |
| Erythrocyte Sedimentation Rate | 16 | 1 |
| X-Ray Imaging | 17 | 1 |
| Classification | 17 | 2 |
| Epidemiology | 19 | 1 |
| Prognosis and Disease Staging | 19 | 1 |
| Measurement of Treatment Effectiveness | 20 | 1 |
| Treatment Options | 21 | 1 |
| Pharmacological | 21 | 1 |
| Disease-Modifying Anti-Rheumatic Drugs | 21 | 1 |
| Methotrexate | 21 | 1 |
| Celebrex (celecoxib) | 21 | 1 |
| Plaquenil (hydroxychloroquine) | 22 | 1 |
| Arava (leflunomide) | 22 | 1 |
| Azulfidine, Salazopyrin (sulfasalazine) | 22 | 1 |
| Neoral (cyclosporine) | 22 | 1 |
| Prograf (tacrolimus) | 22 | 1 |
| Xeljanz (tofacitinib) | 22 | 1 |
| Other Nonbiologics | 23 | 1 |
| Non-Steroidal Anti Inflammatory Drugs | 23 | 1 |
| Painkillers | 23 | 1 |
| Glucocorticoids | 23 | 1 |
| Biologic Disease-Modifying Anti-Rheumatic Drugs | 23 | 1 |
| | 24 | 1 |
| Interleukin-6 Inhibitors | 24 | 1 |
| Other Monoclonal Antibodies | 24 | 1 |
| Anakinra | 25 | 1 |
| Treatment Algorithms and Prescribing Habits | 25 | 3 |
| Non-Pharmacological Care | 28 | 1 |
| Marketed Products | 29 | 19 |
| Therapeutic Landscape | 30 | 1 |
| Remicade (infliximab) - Johnson and Johnson, Merck | 30 | 2 |
| Humira (adalimumab) - Abbott Laboratories | 32 | 2 |
| Enbrel (etanercept) - Amgen Inc., Pfizer Inc. and Takeda Pharmaceutical Co. Ltd. | 34 | 2 |
| Rituxan (rituximab) - Genentech (Roche Group), Biogen IDEC Inc. | 36 | 2 |
| Orencia (abatacept) - Bristol-Myers Squibb | 38 | 2 |
| Actemra (tocilizumab) -F Hoffman La Roche Ltd. | 40 | 2 |
| Simponi (golimumab) - Johnson and Johnson, Merck | 42 | 1 |
| Cimzia (certolizumab pegol) - UCB S.A. | 43 | 1 |
| Remsima (biosimilar infliximab) - Celltrion Inc. | 44 | 1 |
| Comparative Efficacy and Safety | 44 | 3 |
| Unmet Need | 47 | 1 |
| Pipeline for Rheumatoid Arthritis Monoclonal Antibody Therapeutics | 48 | 20 |
| Overall Pipeline | 48 | 1 |
| Molecular Targets in the Pipeline | 49 | 3 |
| Clinical Trials | 52 | 1 |
| Failure Rate | 52 | 4 |
| Patient Enrolment and Clinical Trial Size | 56 | 3 |
| Duration | 59 | 2 |
| Promising Drug Candidates in the Pipeline | 61 | 1 |
| Arzerra (ofatumumab) - Genmab A/S, GlaxoSmithKline Plc. | 61 | 1 |
| LY2127399 (tabalumab) - Eli Lily and Company | 61 | 1 |
| REGN88 (sarilumab) - Regeneron Pharmaceuticals Inc. | 62 | 1 |
| CNTO 136 (sirukumab) - Johnson and Johnson | 62 | 1 |
| AIN457 (secukinumab) - Novartis | 63 | 1 |
| ALD-518 - Alder Biopharmaceuticals Inc. | 63 | 1 |
| BT-061 (tregalizumab) - Biotest A.G. | 63 | 1 |
| MLTA3698A (pateclizumab) - Genentech Inc. | 64 | 1 |
| MOR 103 - MorphoSys A.G. | 64 | 1 |
| Heat Map of Safety and Efficacy for Pipeline and Marketed Products | 65 | 1 |
| Conclusion | 66 | 2 |
| Market Forecast to 2018 | 68 | 22 |
| Geographical Markets | 68 | 1 |
| Global Market | 69 | 2 |
| US | 71 | 1 |
| Treatment Usage Patterns | 71 | 1 |
| Annual Cost of Treatment | 71 | 1 |
| Market Size | 71 | 2 |
| UK | 73 | 1 |
| Treatment Usage Patterns | 73 | 1 |
| Annual Cost of Treatment | 73 | 1 |
| Market Size | 73 | 2 |
| France | 75 | 1 |
| Treatment Usage Patterns | 75 | 1 |
| Annual Cost of Treatment | 75 | 1 |
| Market Size | 75 | 2 |
| Germany | 77 | 1 |
| Treatment Usage Patterns | 77 | 1 |
| Annual Cost of Treatment | 77 | 1 |
| Market Size | 77 | 2 |
| Italy | 79 | 1 |
| Treatment Usage Patterns | 79 | 1 |
| Annual Cost of Treatment | 79 | 1 |
| Market Size | 79 | 2 |
| Spain | 81 | 1 |
| Treatment Usage Patterns | 81 | 1 |
| Annual Cost of Treatment | 81 | 1 |
| Market Size | 81 | 2 |
| Japan | 83 | 1 |
| Treatment Usage Patterns | 83 | 1 |
| Annual Cost of Treatment | 83 | 1 |
| Market Size | 83 | 2 |
| Drivers and Barriers for the mAbs market in Rheumatoid Arthritis | 85 | 1 |
| Drivers | 85 | 1 |
| Repositioning as a Supplementary Revenue Source | 85 | 1 |
| Weak Sales Erosion by Biosimilars | 86 | 1 |
| High Annual Cost of Treatment Still Rising | 87 | 1 |
| Sustained Innovation in Developmental Pipeline | 87 | 1 |
| Barriers | 87 | 1 |
| Difficulty and Expense in the Production of mAbs | 87 | 1 |
| Safety Concerns | 88 | 1 |
| Impending Patent Cliffs | 88 | 2 |
| Deals and Strategic Consolidations | 90 | 11 |
| Mergers and Acquisition Deals | 91 | 1 |
| Amgen Completes Acquisition of Micromet, Inc. | 91 | 1 |
| Pfizer Inc. Completes Acquisition of Wyeth | 92 | 1 |
| Bristol-Myers Squibb Completes Acquisition of Medarex Inc. | 92 | 1 |
| Teva Pharmaceutical Industries Limited Acquires CoGenesys Inc. | 92 | 1 |
| Biotie Therapies Corp. Terminates Acquisition of Newron Pharmaceuticals S.p.A. | 92 | 1 |
| Emergent BioSolutions Inc. Completes Acquisition of Trubion Pharmaceuticals Inc. | 92 | 1 |
| Alexion Pharmaceuticals Inc. completes acquisition of Taligen Therapeutics Inc. | 93 | 1 |
| Ligand Pharmaceuticals Incorporated Completes Acquisition of Pharmacopeia Inc. | 93 | 1 |
| Astellas Pharma Inc. Completes Acquisition of Perseid Therapeutics LLC | 93 | 1 |
| Cypress Bioscience Inc. Completes Acquisition of Proprius Pharmaceuticals Inc. | 93 | 1 |
| Simcere Pharmaceutical Group Completes Acquisition of Shanghai Celgen Bio-Pharmaceutical Co. Ltd. | 93 | 1 |
| Major Co-development Deals | 94 | 1 |
| Abbott Laboratories Enters Worldwide Agreement with Biotest AG | 94 | 1 |
| Dynavax Technologies Corporation Expands Worldwide Agreement with GlaxoSmithKline plc | 95 | 1 |
| Astellas Pharma Inc. Enters into Agreement with Maxygen Inc. | 95 | 1 |
| Tanabe Research Laboratories Enters Agreement with Anaphore Inc. | 95 | 1 |
| Major Licensing Deals | 96 | 3 |
| Hanwha Chemical Corporation Enter Licensing Agreement with Merck Sharp and Dohme Research Ltd. | 99 | 1 |
| Alder Biopharmaceuticals Inc. Enter Agreement with Bristol-Myers Squibb Company | 99 | 1 |
| Immunomedics Inc. Enter Agreement with Nycomed International Management GmbH | 99 | 1 |
| Sanofi-Aventis Enter Agreement with Kyowa Hakko Kogyo Co. Ltd. | 99 | 1 |
| EUSA Pharma Inc. Enter Licensing Agreement with GlaxoSmithKline plc | 100 | 1 |
| Appendix | 101 | 34 |
| All Pipeline Drugs by Phase | 101 | 11 |
| Discovery | 101 | 1 |
| Preclinical | 102 | 4 |
| IND-Filed and Phase 0 | 106 | 1 |
| Phase I | 106 | 2 |
| Phase II | 108 | 2 |
| Phase III | 110 | 1 |
| Undisclosed | 111 | 1 |
| Market Forecasts to 2018 | 112 | 9 |
| Global | 112 | 1 |
| United States | 113 | 1 |
| Top Five European Countries (Aggregate) | 114 | 1 |
| UK | 115 | 1 |
| France | 116 | 1 |
| Germany | 117 | 1 |
| Italy | 118 | 1 |
| Spain | 119 | 1 |
| Japan | 120 | 1 |
| Market Definitions | 121 | 1 |
| Abbreviations | 121 | 2 |
| References for Heat Maps (Figure 12 and Figure 23) | 123 | 2 |
| Sources | 125 | 5 |
| Research Methodology | 130 | 5 |
| Coverage | 130 | 1 |
| Secondary Research | 130 | 1 |
| Primary Research | 131 | 1 |
| Therapeutic Landscape | 131 | 1 |
| Epidemiology-Based Forecasting | 132 | 1 |
| Market Size by Geography | 133 | 1 |
| Geographical Landscape | 134 | 1 |
| Pipeline Analysis | 134 | 1 |
| Expert Panel Validation | 134 | 1 |
| Contact Us | 134 | 1 |
| Disclaimer | 134 | 1 |